SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Miyoshi K. The concept of BPSD. Jpn J Clin Psychiatry 2000; 29: 12091215 (in Japanese).
  • 2
    Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published erratum appears in Neurology 2001; 57: 2153]. Neurology 2001; 57: 613620.
  • 3
    Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002; 14: 389404.
  • 4
    Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr Med Res Opin 2002; 18: 347354.
  • 5
    Hori K, Inada T, Oda T, Tominaga I, Hoshina M, Takeshita H. Effects of donepezil hydrochloride on behavioral and psychological signs and symptoms of Alzheimer type dementia: Discussion of two case reports. Seishin Igaku 2001; 43: 555558 (in Japanese).
  • 6
    Tanigawa M, Shiroma S, Koja S, Tamura Y, Miyazato Y. Improvement of BPSD by donepezil hydrochloride and risperidone in a patient with senile dementia of the Alzheimer type. Seishin Igaku 2003; 45: 8486 (in Japanese).
  • 7
    Tanigawa M, Shiroma S, Koja S, Tamura Y, Miyazato Y.The efficacy of donepezil hydrochloride on behavioral and psychological symptoms of dementia in four patients with Alzheimer's disease. Jpn J Psychiatr Treat 2003; 18: 833837 (in Japanese).
  • 8
    Japanese Society of Neurology Therapeutic Guidelines Ad Hoc Committee. Japanese Society of Neurology Therapeutic Guidelines. Rinsho Shinkeigaku 2002; 42: 781833 (in Japanese).